— Know what they know.
Not Investment Advice

OTLC OTC

Oncotelic Therapeutics, Inc.
1W: -17.0% 1M: -40.7% 3M: -49.9% YTD: -73.0% 1Y: -69.5% 3Y: -30.0% 5Y: -83.8%
$0.02
-0.00 (-1.41%)
 
Weekly Expected Move ±11.9%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 40 · $9.3M mcap · 223M float · 0.126% daily turnover · Short 75% of daily vol

Balance Sheet Trends

Total Assets
$27M -11.1% ▼
5Y CAGR: +2.4%
Total Liabilities
$19M +4.3% ▲
5Y CAGR: +23.1%
Shareholders Equity
$8M -32.0% ▼
5Y CAGR: -13.4%
Cash & Investments
$86K -49.5% ▼
5Y CAGR: +1.0%
Total Debt
$13M +4.1% ▲
5Y CAGR: +54.2%
Net Debt
$13M +4.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$474K$569K$241K$170K$86K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$474K$569K$241K$170K$86K
Net Receivables$20K$20K$20K$19K$19K
Inventory$0$20K$0$0$0
Other Current Assets$20K$20K$42K$39K$29K
Total Current Assets$616K$627K$303K$272K$134K
Property, Plant & Equip.$10K$0$0$0$0
Goodwill & Intangibles$23M$23M$13M$7M$4M
Long-Term Investments$0$0$23M$23M$23M
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$23M$23M$36M$30M$27M
Total Assets$24M$24M$36M$30M$27M
— Liabilities —
Accounts Payable$2M$2M$2M$2M$2M
Short-Term Debt$5M$9M$11M$11M$13M
Deferred Revenue$1M$2M$0$0$0
Other Current Liabilities$3M$3M$3M$3M$3M
Total Current Liabilities$11M$15M$17M$17M$19M
Long-Term Debt$0$0$0$2M$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$709M$203M$13M$2M$0
Total Liabilities$11M$15M$17M$18M$19M
— Equity —
Common Stock$906K$4M$4M$4M$4M
Retained Earnings-$22M-$31M-$26M-$34M-$38M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$12M$8M$19M$12M$8M
Total Liabilities & Equity$24M$24M$36M$30M$27M
— Key Metrics —
Total Debt$5M$9M$11M$13M$13M
Net Debt$5M$8M$11M$12M$13M
Total Investments$0$0$23M$23M$23M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms